A Ubiquitin Ligase Transfers Preformed Polyubiquitin Chains from a Conjugating Enzyme to a Substrate
Authors
Affiliations
In eukaryotic cells, many short-lived proteins are conjugated with Lys 48-linked ubiquitin chains and degraded by the proteasome. Ubiquitination requires an activating enzyme (E1), a conjugating enzyme (E2) and a ligase (E3). Most ubiquitin ligases use either a HECT (homologous to E6-associated protein C terminus) or a RING (really interesting new gene) domain to catalyse polyubiquitination, but the mechanism of E3 catalysis is poorly defined. Here we dissect this process using mouse Ube2g2 (E2; identical at the amino acid level to human Ube2g2) and human gp78 (E3), an endoplasmic reticulum (ER)-associated conjugating system essential for the degradation of misfolded ER proteins. We demonstrate by expressing recombinant proteins in Escherichia coli that Ube2g2/gp78-mediated polyubiquitination involves preassembly of Lys 48-linked ubiquitin chains at the catalytic cysteine of Ube2g2. The growth of Ube2g2-anchored ubiquitin chains seems to be mediated by an aminolysis-based transfer reaction between two Ube2g2 molecules that each carries a ubiquitin moiety in its active site. Intriguingly, polyubiquitination of a substrate can be achieved by transferring preassembled ubiquitin chains from Ube2g2 to a lysine residue in a substrate.
Zhao A, Zhou C, Li J, Wang Z, Zhu H, Shen S Acta Pharm Sin B. 2025; 14(12):5201-5218.
PMID: 39807310 PMC: 11725101. DOI: 10.1016/j.apsb.2024.09.005.
Qiao Z, Li D, Zhang F, Zhu J, Liu S, Bai X PLoS Pathog. 2025; 21(1):e1012843.
PMID: 39761299 PMC: 11737852. DOI: 10.1371/journal.ppat.1012843.
Characterizing the Monomer-Dimer Equilibrium of UbcH8/Ube2L6: A Combined SAXS and NMR Study.
Kahraman K, Robson S, Gocenler O, Yenici C, Tozkoparan Ceylan C, Klein J ACS Omega. 2024; 9(38):39564-39572.
PMID: 39346869 PMC: 11425648. DOI: 10.1021/acsomega.4c03610.
Characterizing the monomer-dimer equilibrium of UbcH8/Ube2L6: A combined SAXS and NMR study.
Kahraman K, Robson S, Gocenler O, Yenici C, Tozkoparan C, Klein J bioRxiv. 2023; .
PMID: 37090523 PMC: 10120734. DOI: 10.1101/2023.04.13.536743.
Clinicopathological Features and Prognostic Evaluation of UBR5 in Liver Cancer Patients.
Huo Q, Hu J, Hou B, Zhao M, Han X, Du Y Pathol Oncol Res. 2022; 28:1610396.
PMID: 36388433 PMC: 9665233. DOI: 10.3389/pore.2022.1610396.